Funder: National Institutes of Health

Due Dates: May 16, 2025 (New/Renewal/Resubmission/Revision) | September 17, 2025 | January 16, 2026 | May 15, 2026 | September 17, 2026 | January 15, 2027

Funding Amounts: Up to $350,000 direct costs per year; project period up to 3 years (max 2 years for R61, max 2 years for R33)

Summary: Supports early-stage translational research to develop non-addictive pain therapeutics, advancing projects toward preclinical drug discovery milestones.

Key Information: Clinical trials are not allowed; strong biological rationale and clear milestones are required; limited submission—see eligibility.